Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Oncology Letters

• Publication date

  2018-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/ol.2018.7859PMID 29541220PMCID PMC5835849
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Eighth Edition Lung Cancer Stage Classification

  2017cited by this paper
• The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations

  2016cited by this paper
• Hot spot mutations in Finnish non-small cell lung cancers.

  2016cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• TGF-β/Smad signaling through DOCK4 facilitates lung adenocarcinoma metastasis

  2015cited by this paper
• Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.

  2015cited by this paper
• Clinical next generation sequencing to identify actionable aberrations in a phase I program

  2015cited by this paper
• A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

  2015cited by this paper
• Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets

  2015cited by this paper
• Clinical next‐generation sequencing in patients with non–small cell lung cancer

  2015cited by this paper
• Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)

  2015cited by this paper
• Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.

  2015cited by this paper
• Lung cancer: Biology and treatment options.

  2015cited by this paper
• Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology

  2014cited by this paper
• Crizotinib in ROS1-rearranged non-small-cell lung cancer.

  2014cited by this paper
• BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.

  2014cited by this paper
• Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

  2014cited by this paper
• Comprehensive molecular profiling of lung adenocarcinoma

  2014cited by this paper
• Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC

  2014cited by this paper
• Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

  2013cited by this paper
• The impact of genomic changes on treatment of lung cancer.

  2013cited by this paper
• Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cited by this paper
• Genomic medicine frontier in human solid tumors: prospects and challenges.

  2013cited by this paper
• Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.

  2013cited by this paper
• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

  2013cited by this paper
• Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment.

  2012cited by this paper
• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

  2012cited by this paper
• Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition

  2012cited by this paper
• [Management of brain metastases from non-small cell lung carcinoma].

  2011cited by this paper
• KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.

  2010cited by this paper
• The management of brain metastases in patients with non-small cell lung cancer-is it time to go back to the drawing board?

  2010cited by this paper
• Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

  2008cited by this paper
• A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).

  2004cited by this paper
• Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

  2004cited by this paper
• Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers

  2000cited by this paper
• Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors.

  1997cited by this paper
• Splicing mutations of the p53 gene in human hepatocellular carcinoma.

  1993cited by this paper
• Mutation in the TP53 gene in colorectal carcinoma detected by polymerase chain reaction

  1991cited by this paper

• Cancer brain metastasis: molecular mechanisms and therapeutic strategies

  2025cites this paper
• Concurrent mutations in multiple tumor suppressor genes correlate with adverse prognosis in stage I lung adenocarcinoma patients

  2025cites this paper
• TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases

  2024influential citation
• Genomic landscape and actionable mutations of brain metastases derived from non–small cell lung cancer: A systematic review

  2023cites this paper
• Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer

  2022influential citation
• Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: A review of the literature.

  2021cites this paper
• Molecular Profiles of Brain Metastases: A Focus on Heterogeneity

  2021influential citation
• Genomic Mutations of Primary and Metastatic Lung Adenocarcinoma in Chinese Patients

  2020cites this paper
• Genetic Heterogeneity Between Paired Primary and Brain Metastases in Lung Adenocarcinoma

  2020cites this paper
• Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.

  2020cites this paper
• Effects of single-nucleotide polymorphisms in the mTORC1 pathway on the risk of brain metastasis in patients with non-small cell lung cancer

  2019cites this paper